Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 7/20 | 0.41 |
| ▸ | RPS6KA4 | O75676 | 3/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28849705 | 0.88 | RPS6KA5 (0.40) | RPS6KA5RPS6KA4ELANEEGFRHDAC6 | |
| SCHEMBL29114227 | 0.87 | RPS6KA5 (0.42) | RPS6KA5RPS6KA4ELANEEGFRHDAC6 | |
| SCHEMBL30626966 | 0.75 | KMT2A (0.44) | SLC22A12 | |
| SCHEMBL30241905 | 0.73 | SLC22A12 (0.56) | RPS6KA5RPS6KA4ELANESLC22A12MET | |
| SCHEMBL288413 | 0.73 | SLC22A12 (0.56) | RPS6KA5RPS6KA4ELANESLC22A12MET | |
| SCHEMBL17714320 | 0.72 | RPS6KA5 (0.36) | RPS6KA5RPS6KA4ELANEEGFRSLC22A12 | |
| SCHEMBL30533169 | 0.72 | TRPV1 (0.33) | — | |
| SCHEMBL8390810 | 0.72 | RPS6KA5 (0.37) | RPS6KA5RPS6KA4HDAC6HDAC1 | |
| SCHEMBL29665757 | 0.71 | MKNK2 (0.41) | EGFRSLC22A12ALDH1A1IRAK4 | |
| SCHEMBL4417290 | 0.71 | MKNK2 (0.41) | EGFRSLC22A12ALDH1A1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805357-A | Small molecule inhibitor targeting SETDB1-TTD and pharmaceutical application thereof | 四川大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-111499639-B | Pyrimidone derivatives and their use in pharmacy | 四川大学华西医院 | 2022-03-04 | — | — | CN | disclosed |
| CN-111499639-A | Pyrimidone derivatives and their use in pharmacy | 四川大学华西医院 | 2020-08-07 | — | — | CN | disclosed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
| CN-101056878-A | Azaindole carboxamides | SCHVARZ PHARMA AG (DE) | 2007-10-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | RPS6KA5 628/4885RPS6KA4 924/4885ELANE 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.